Design of chimeric antigen receptors with integrated controllable transient functions

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Juillerat, Alexandre ^a   Marechal, Alan ^a   Filhol, Jean Marie ^a   Valton, Julien ^a   Duclert, Aymeric ^a   Poirot, Laurent ^a   Duchateau, Philippe ^a  

^a Arvid Wallgrens Backe 20   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AP 21967; CD8 ANTIGEN; CD8 ANTIGEN, ALPHA CHAIN; CHIMERIC PROTEIN; LYMPHOCYTE ANTIGEN RECEPTOR; RAPAMYCIN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TACROLIMUS;

ANALOGS AND DERIVATIVES; CHEMISTRY; COCULTURE; CYTOLOGY; CYTOTOXICITY; DRUG EFFECTS; GENE EXPRESSION; GENE VECTOR; GENETIC ENGINEERING; GENETIC TRANSFECTION; GENETICS; HUMAN; IMMUNOLOGY; PROCEDURES; PROTEIN DOMAIN; T LYMPHOCYTE; TUMOR CELL LINE;

ANTIGENS, CD8; CELL LINE, TUMOR; COCULTURE TECHNIQUES; CYTOTOXICITY, IMMUNOLOGIC; GENE EXPRESSION; GENETIC ENGINEERING; GENETIC VECTORS; HUMANS; MUTANT CHIMERIC PROTEINS; PROTEIN DOMAINS; RECEPTORS, ANTIGEN, T-CELL; SINGLE-CHAIN ANTIBODIES; SIROLIMUS; T-LYMPHOCYTES; TACROLIMUS; TRANSFECTION;

EID: 84954059507     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep18950     Document Type: Article

References (36)

1. Sharpe, M. & Mount, N. Genetically modified T cells in cancer therapy: opportunities and challenges. Dis Model Mech 8, 337-350 (2015).
2. Brentjens, R. J. et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med 5, 177ra138 (2013).
3. Grupp, S. A. et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 368, 1509-1518 (2013).
4. Kalos, M. et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 3, 95ra73 (2011).
5. Porter, D. L., Levine, B. L., Kalos, M., Bagg, A. & June, C. H. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 365, 725-733 (2011).
6. Brentjens, R. J. et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 118, 4817-4828 (2011).
7. Davila, M. L. et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med 6, 224ra225 (2014).
8. Morgan, R. A. et al. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 18, 843-851 (2010).
9. Budde, L. E. et al. Combining a CD20 chimeric antigen receptor and an inducible caspase 9 suicide switch to improve the efficacy and safety of T cell adoptive immunotherapy for lymphoma. PLoS One 8, e82742 (2013).
10. Chen, Y. Y., Jensen, M. C. & Smolke, C. D. Genetic control of mammalian T-cell proliferation with synthetic RNA regulatory systems. Proc Natl Acad Sci USA 107, 8531-8536 (2010).
11. Narayanan, P. et al. A composite MyD88/CD40 switch synergistically activates mouse and human dendritic cells for enhanced antitumor efficacy. J Clin Invest 121, 1524-1534 (2011).
12. Marin, V. et al. Comparison of different suicide-gene strategies for the safety improvement of genetically manipulated T cells. Hum Gene Ther Methods 23, 376-386 (2012).
13. Philip, B. et al. A highly compact epitope-based marker/suicide gene for easier and safer T-cell therapy. Blood 124, 1277-1287 (2014).
14. Straathof, K. C. et al. An inducible caspase 9 safety switch for T-cell therapy. Blood 105, 4247-4254 (2005).
15. James, J. R. & Vale, R. D. Biophysical mechanism of T-cell receptor triggering in a reconstituted system. Nature 487, 64-69 (2012).
16. Wu, C. Y., Roybal, K. T., Puchner, E. M., Onuffer, J. & Lim, W. A. Remote control of therapeutic T cells through a small molecule-gated chimeric receptor. Science (2015).
17. Banaszynski, L. A., Liu, C. W. & Wandless, T. J. Characterization of the FKBP.rapamycin.FRB ternary complex. J Am Chem Soc 127, 4715-4721 (2005).
18. Chen, J., Zheng, X. F., Brown, E. J. & Schreiber, S. L. Identification of an 11-kDa FKBP12-rapamycin-binding domain within the 289-kDa FKBP12-rapamycin-associated protein and characterization of a critical serine residue. Proc Natl Acad Sci USA 92, 4947-4951 (1995).
19. Kinet, J. P. The high-affinity IgE receptor (Fc epsilon RI): from physiology to pathology. Annu Rev Immunol 17, 931-972 (1999).
20. Kraft, S. & Kinet, J. P. New developments in FcepsilonRI regulation, function and inhibition. Nat Rev Immunol 7, 365-378 (2007).
21. Kugler, M. et al. Stabilization and humanization of a single-chain Fv antibody fragment specific for human lymphocyte antigen CD19 by designed point mutations and CDR-grafting onto a human framework. Protein Eng Des Sel 22, 135-147 (2009).
22. Poirot, L. et al. Multiplex genome edited T-cell manufacturing platform for "off-the-shelf " adoptive T-cell immunotherapies. Cancer Res (2015).
23. Wang, E. et al. Generation of Potent T-cell Immunotherapy for Cancer Using DAP12-Based, Multichain, Chimeric Immunoreceptors. Cancer Immunol Res 3, 815-826 (2015).
24. Huye, L. E. et al. Combining mTor inhibitors with rapamycin-resistant T cells: a two-pronged approach to tumor elimination. Mol Ther 19, 2239-2248 (2011).
25. Bayle, J. H. et al. Rapamycin analogs with differential binding specificity permit orthogonal control of protein activity. Chem Biol 13, 99-107 (2006).
26. Cloughesy, T. F. et al. Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med 5, e8 (2008).
27. Wilson, K. P. et al. Comparative X-ray structures of the major binding protein for the immunosuppressant FK506 (tacrolimus) in unliganded form and in complex with FK506 and rapamycin. Acta Crystallogr D Biol Crystallogr 51, 511-521 (1995).
28. Cabantous, S. et al. A new protein-protein interaction sensor based on tripartite split-GFP association. Sci Rep 3, 2854 (2013).
29. Valton, J. et al. A Multidrug-resistant Engineered CAR T Cell for Allogeneic Combination Immunotherapy. Mol Ther (2015).
30. Dotti, G., Gottschalk, S., Savoldo, B. & Brenner, M. K. Design and development of therapies using chimeric antigen receptor-expressing T cells. Immunol Rev 257, 107-126 (2014).
31. Sadelain, M., Brentjens, R. & Riviere, I. The basic principles of chimeric antigen receptor design. Cancer Discov 3, 388-398 (2013).
32. Minagawa, K., Zhou, X., Mineishi, S. & Di Stasi, A. Seatbelts in CAR therapy: How Safe Are CARS? Pharmaceuticals (Basel) 8, 230-249 (2015).
33. Chakravarti, D. & Wong, W. W. Synthetic biology in cell-based cancer immunotherapy. Trends Biotechnol 33, 449-461 (2015).
34. Beatty, G. L. et al. Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. Cancer Immunol Res 2, 112-120 (2014).
35. Adusumilli, P. S. et al. Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity. Sci Transl Med 6, 261ra151 (2014).
36. Stephan, S. B. et al. Biopolymer implants enhance the efficacy of adoptive T-cell therapy. Nat Biotechnol 33, 97-101 (2015).